ED in Europe: A Rising Tide?
Executive SummaryWorldwide launches of new PDE5 inhibitors to treat erectile dysfunction are certain to expand the global market for these and other ED therapies. But in Europe, Viagra's brand ubiquity, the prohibition of DTC advertising, and disparate national markets present challenges to firms hoping to dethrone the Pfizer juggernaut.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.